Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults

This study has been completed.

Study NCT00073216 Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

First Received: November 18, 2003 Last Updated: March 9, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	August 2009 (Final data collection date for primary outcome measure)

No publications provided by National Institute of Allergy and Infectious Diseases (NIAID)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Spearman P, Lally MA, Elizaga M, Montefiori D, Tomaras GD, McElrath MJ, Hural J, De Rosa SC, Sato A, Huang Y, Frey SE, Sato P, Donnelly J, Barnett S, Corey LJ; HIV Vaccine Trials Network of NIAID. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis. 2011 Apr 15;203(8):1165-73.